NLA Partners with PlatformQ Health on CME Series Aimed at Reducing CVD Risk

Clinicians treating patients with elevated LDL-C levels are invited to participate in a new complimentary online CME series on CardioCareLive.com. Stay abreast of PCSK9 inhibitors and their role in decreasing risk of cardiovascular disease. High cholesterol — particularly a high level of low-density lipoprotein cholesterol (LDL-C) — is a main risk factor for developing cardiovascular disease (CVD), the number one cause of death in the United States.